openPR Logo
Press release

Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 2022

05-18-2017 02:53 PM CET | Health & Medicine

Press release from: Transparency Market Research

Glioblastoma Multiforme Treatment (GBM) Market Will Increase

Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). In case of GBM treatment, there are many restraints and challenges such as its resistance against DNA-modifying agents, migration of malignant cells into adjacent brain tissues increases the complexity of the surgery, and current FDA approved treatments may cause neurotoxicity in patients. Thus, as available treatment options lack in efficiency, the mortality rate of glioblastoma is characterized by rapid progression and poor survival rate with only 8.7% of the patients surviving more than two years post diagnosis. According to Centers for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumors of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence.

Obtain Report Details @http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

Although, the rising mortality rate of GBM has made it one of the lethal type of cancers; the pipeline of GBM is well equipped with various types of novel therapies including immunotherapy, biologics, small molecules and other drugs. The pipeline of GBM is currently rich in number of various therapeutic drugs and devices that are expected to receive FDA approvals for conducting the clinical trials. The FDA approved drugs currently present in market are temozolomide (Temodar, Temodal and Temcad), bevacizumab (Avastin) and carmustine wafers (BiCNU). The geographical segmentation of GBM market comprises North America, Europe, Asia Pacific and Rest of the World. Bevacizumab (Avastin) is the latest addition to this artillery, while temozolomide was leading the GBM market in 2013 due to it’s effectiveness when combined with surgery. Bevacizumab is the first monoclonal antibody drug approved for GBM treatment which is more efficient than temozolomide and is expected to surpass its revenue by 2016. Temozolomide market was drastically affected in 2013 as it has lost the market exclusivity in 2012 and generics manufactured by Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market. Geographically, in 2013 North America was observed as the most leading GBM market due to increasing support from government and non-government organizations to raise public awareness by and advanced healthcare infrastructure to boost the pipeline research in this market. Asia Pacific is the fastest growing market, rising awareness against GBM is boosting the diagnostic rate in this region and developing healthcare infrastructure is also assisting the market growth.

The pipeline analysis of GBM treatment include biologics, small molecules, devices, surgeries, and immunotherapy. In the current scenario, the pipeline review of glioblastoma seems to be strong as more than 50 molecules are in phase I and phase II clinical trials. The most promising drugs in phase III trials are Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These molecules have performed well in phase II of the clinical trials in terms of exceeding the overall survival rate.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4807

The key players involved in the GBM market are Abbvie, Inc., Celldex Therapeutics, Inc., Exellixis, Inc., Brostol-Myers Squibb Co. and F. Hoffman La Roche. In 2013, F. Hoffman La Roche was observed to be the most promising and efficient source of GBM treatment due to its novel drug delivery system known as “brain shuttle.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 2022 here

News-ID: 541506 • Views: 374

More Releases from Transparency Market Research

Global Genome Engineering Market: Business Growth, Development Factors, Applicat …
TMR’s report on the global genome engineering market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global genome engineering market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth
Sintering Process Market Growth Trends, Current Demand, and Development Report
Global Sintering Process Market: Snapshot The global sintering process market is prophesied to gain largely from the competent flourish of powder metallurgy and its applications in a range of industries. Power metallurgy-based process routes incorporating hot isostatic pressing (HIP) and exceptionally good properties are mainly employed in land-based and aero-engine gas turbine applications. Titanium powder metallurgy gathers a growing interest in the airframe industry for weight reduction in replacement steel parts
Medical Textiles Market Report Analysis: Emerging Trends, Business Growth Opport …
Global Medical Textiles Market: Snapshot The global medical textiles market is growing on the back of plethora of reasons. The government bodies of many worldwide countries have introduced diverse stringent regulations that compel the use of medical textiles. At the same time, these government organizations are offering financial support for non-implantable goods. These factors are working as key drivers for the development of the global medical textiles market. An upcoming research report
Anti-Hypertensive Drugs Market Industry Analysis Size, Share, Trend, Business Op …
Global Anti-Hypertensive Drugs Market: Overview Hypertension is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Also referred to as arterial hypertension or high blood pressure in generic terms, the condition is measured in terms of systolic and diastolic pressure. At rest blood pressure level is in the range of 120-140 mm Hg systolic and 60-90mm Hg diastolic. Hypertension arises when it is persistently

All 5 Releases


More Releases for GBM

Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Multiforme Treatment (GBM) Market is exhibiting a positive CAGR of …
Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents. Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary: ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure,